CRXM:OTO-Taxus Cardium Pharmaceuticals Group Inc (USD)

COMMON STOCK | Biotechnology | OTC Pink

Last Closing

USD 0.0001

Change

0.00 (0.00)%

Market Cap

USD 3.30M

Volume

N/A

Analyst Target

USD 2.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Taxus Cardium Pharmaceuticals Group Inc is a regenerative medicine biotechnology company focused on the development of advanced regenerative therapeutics.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

+6.50 (+4.89%)

USD 599.53B
CSLLY CSL Ltd

-0.12 (-0.13%)

USD 90.20B
CMXHF CSL Limited

-1.75 (-0.93%)

USD 90.20B
UCBJF UCB SA

N/A

USD 26.60B
UCBJY UCB SA ADR

-0.05 (-0.07%)

USD 26.44B
ARGNF argenx SE

N/A

USD 22.20B
GNMSF Genmab A/S

-19.63 (-6.81%)

USD 18.02B
WXIBF WuXi Biologics

N/A

USD 7.05B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.91B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 6.91B

ETFs Containing CRXM

ZIG The Acquirers Fund ETF 3.75 % 0.00 %

-0.96 (-2.53%)

USD 0.05B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -99.94% 7% C- 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.94% 6% D- 3% F
Average Annual (5 Year Horizon)  
Capital Gain -31.91% 17% F 7% C-
Dividend Return -31.91% 17% F 7% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 130.98% 37% F 28% F
Risk Adjusted Return -24.36% 35% F 23% F
Market Capitalization 3.30M 3% F 1% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.